Oncology

Back to articles

Enzalutamide improves survival in late-stage prostate cancer

KEY POINT

Enzalutamide (Xtandi—Astellas, Medivation) significantly lengthened survival time in men with castration-resistant prostate cancer after chemotherapy, according to a recent study that led to the agent’s FDA approval.

SOURCES

Scher HI et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.